(Q46608987)

23 December 2017

title

Scenarios on costs and savings of influenza treatment and prevention for Dutch healthy working adults (English)

1 reference

23 December 2017

1

Maarten J Postma

1 reference

23 December 2017

author name string

Paul Jansema

series ordinal

2

1 reference

23 December 2017

Huib W K F H Scheijbeler

series ordinal

3

1 reference

23 December 2017

Marianne L L van Genugten

series ordinal

4

1 reference

23 December 2017

language of work or name

English

0 references

publication date

1 July 2005

1 reference

23 December 2017

published in

Vaccine

1 reference

23 December 2017

volume

23

1 reference

23 December 2017

issue

46-47

1 reference

23 December 2017

page(s)

5365-5371

1 reference

23 December 2017

Economic evaluation of influenza vaccination. Assessment for The Netherlands

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.007

Pharmacoeconomics of influenza vaccination for healthy working adults: reviewing the available evidence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.007

Pharmacoeconomics of influenza vaccination in the elderly: reviewing the available evidence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.007

Is immunising all patients with chronic lung disease in the community against influenza cost effective? Evidence from a general practice based clinical prospective cohort study in Utrecht, The Netherlands

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.007

Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.007

Cost-benefit analysis of a strategy to vaccinate healthy working adults against influenza.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.007

Pandemic Influenza and Healthcare Demand in the Netherlands: Scenario Analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.007

Zanamivir in the prevention of influenza among healthy adults: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.007

Efficacy and safety of the neuraminidase inhibitor zanamivirin the treatment of influenza A and B virus infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.007

Estimating influenza-related hospitalization in The Netherlands

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.007

Prevention and early treatment of influenza in healthy adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.007

The impact of influenza and influenza-like illness on productivity and healthcare resource utilization in a working population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.007

Influenza vaccine efficacy in young, healthy adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.007

Efficacy of repeated annual immunization with inactivated influenza virus vaccines over a five year period

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.007

Effectiveness and cost-benefit of influenza vaccination of healthy working adults: A randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.007

Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.007

Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.007

Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.007

Side effects associated with influenza vaccination in healthy working adults. A randomized, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.007

Reassessment of the Association between Guillain-Barré Syndrome and Receipt of Swine Influenza Vaccine in 1976–1977: Results of a Two-State Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.007

Cost-effectiveness analysis of pneumococcal vaccination for elderly individuals in The Netherlands.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.007

Probabilistic sensitivity analysis using Monte Carlo simulation. A practical approach

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.007

Oseltamivir for treatment of influenza in healthy adults: pooled trial evidence and cost-effectiveness model for Canada

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.007

Economic costs of influenza-related work absenteeism.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.007

Cost-effectiveness of the influenza vaccine in a healthy, working-age population.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.007

Clinical effectiveness of influenza vaccination in persons younger than 65 years with high-risk medical conditions: the PRISMA study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.06.007

10.1016/J.VACCINE.2005.06.007

7 January 2021

Identifiers

DOI

1 reference

23 December 2017

1 reference

23 December 2017